Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Market Cap : €725.0 Mil (As of Mar. 26, 2025)

View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Biocytogen Pharmaceuticals (Beijing) Co's share price for the quarter that ended in Jun. 2024 was €0.795. Biocytogen Pharmaceuticals (Beijing) Co's Shares Outstanding (EOP) for the quarter that ended in Jun. 2024 was 398.4 Mil. Therefore, Biocytogen Pharmaceuticals (Beijing) Co's market cap for the quarter that ended in Jun. 2024 was €316.7 Mil.

Biocytogen Pharmaceuticals (Beijing) Co's quarterly market cap declined from Jun. 2023 (€958.6 Mil) to Dec. 2023 (€685.0 Mil) and declined from Dec. 2023 (€685.0 Mil) to Jun. 2024 (€316.7 Mil).

Biocytogen Pharmaceuticals (Beijing) Co's annual market cap increased from Dec. 2021 (€0.0 Mil) to Dec. 2022 (€1,182.2 Mil) but then declined from Dec. 2022 (€1,182.2 Mil) to Dec. 2023 (€685.0 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Biocytogen Pharmaceuticals (Beijing) Co's Enterprise Value for Today is €749.0 Mil.

Biocytogen Pharmaceuticals (Beijing) Co Market Cap Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Market Cap Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Market Cap

1,182.22

684.99

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Market Cap	Get a 7-Day Free Trial			-	1,182.22	958.56	684.99	316.69

Competitive Comparison of Biocytogen Pharmaceuticals (Beijing) Co's Market Cap

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocytogen Pharmaceuticals (Beijing) Co's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's Market Cap distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's Market Cap falls into.

Biocytogen Pharmaceuticals (Beijing) Co Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Biocytogen Pharmaceuticals (Beijing) Co's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )	=	Share Price (A: Dec. 2023 )	*	Shares Outstanding (EOP) (A: Dec. 2023 )
	=	€1.72	*	398.250
	=	€685.0

Biocytogen Pharmaceuticals (Beijing) Co's Market Cap for the quarter that ended in Jun. 2024 is calculated as

Market Cap (Q: Jun. 2024 )	=	Share Price (Q: Jun. 2024 )	*	Shares Outstanding (EOP) (Q: Jun. 2024 )
	=	€0.795	*	398.350
	=	€316.7

Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Biocytogen Pharmaceuticals (Beijing) Co Market Cap Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (FRA:I54) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

02315:Hong Kong

Address

12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN

Website

https://www.biocytogen.com.cn

Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines